Beyond the API: Mapping the Secondary Patent Thicket to Forecast Generic Entry
A practitioner’s guide for pharmaceutical analysts, generics strategists, and investors who need to know when a drug is actually off-patent. […]
Beyond the API: Mapping the Secondary Patent Thicket to Forecast Generic Entry Read Post »









